LEADER 03868nam  2200841Ia 450 
001 9910140728903321
005 20251017110125.0
010   $a9786612697135
010   $a9781282697133
010   $a1282697137
010   $a9789240685123
010   $a924068512X
035   $a(CKB)2670000000033540
035   $a(EBL)557633
035   $a(OCoLC)650859957
035   $a(SSID)ssj0000419097
035   $a(PQKBManifestationID)11251989
035   $a(PQKBTitleCode)TC0000419097
035   $a(PQKBWorkID)10378119
035   $a(PQKB)10421859
035   $a(MiAaPQ)EBC557633
035   $a(Au-PeEL)EBL557633
035   $a(CaPaEBR)ebr10404019
035   $a(CaONFJC)MIL269713
035   $a(DNLM)1509874
035   $a(EXLCZ)992670000000033540
100   $a20090102d2009      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aGuidelines for the psychosocially assisted pharmacological treatment of opioid dependence
205   $a1st ed.
210   $aGeneva, Switzerland $cWorld Health Organization$d2009
215   $a1 online resource (132 pages)
300   $aDescription based upon print version of record.
311 08$aPrint version: World Health Organization. Department of Mental Health and Substance Abuse. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva : World Health Organization, ©2009 9789241547543 (OCoLC)297148793 
320   $aIncludes bibliographical references (p. 96-111).
327   $aCOVER; TITLE; COPYRIGHT; Contents; Acknowledgements; Abbreviations and acronyms; Executive summary; Summary of recommendations; 1 Scope and purpose; 2 Method of formulating recommendations; 3 Background; 4 Guidelines for health systems at national and subnational levels; 5 Programme level guidelines - for programme managers and clinical leaders; 6 Patient level guidelines - for clinicians; AnnexES
330   $aThese Guidelinesreview the use of medicines such as methadone, buprenorphine, naltrexone and clonidine in combination with psychosocial support in the treatment of people dependent on heroin or other opioids. Based on systematic reviews of the literature and using the GRADE approach to determining evidence quality, the guidelines contain specific recommendations on the range of issues faced in organizing treatment systems, managing treatment programmes and in treating people dependent on opioids. Developed in collaboration with internationally acclaimed experts from the different regions of th
606   $aOpioid abuse
606   $aDrug abuse
606   $aCombined modality therapy
606   $aOpioid-Related Disorders$xdrug therapy
606   $aOpioid-Related Disorders$xpsychology
606   $aSubstance-Related Disorders$xprevention & control
606   $aBehavior Therapy
606   $aMethadone
606   $aBuprenorphine$xtherapeutic use
606   $aNaltrexone$xtherapeutic use
606   $aCombined Modality Therapy
608   $aGuideline.
615  0$aOpioid abuse.
615  0$aDrug abuse.
615  0$aCombined modality therapy.
615  2$aOpioid-Related Disorders$xdrug therapy.
615  2$aOpioid-Related Disorders$xpsychology.
615  2$aSubstance-Related Disorders$xprevention & control.
615  2$aBehavior Therapy.
615  2$aMethadone.
615  2$aBuprenorphine$xtherapeutic use.
615  2$aNaltrexone$xtherapeutic use.
615  2$aCombined Modality Therapy.
676   $a616.8632061
712 02$aWorld Health Organization.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910140728903321
996   $aGuidelines for the psychosocially assisted pharmacological treatment of opioid dependence$92064785
997   $aUNINA